WHO approved the new \u201cMade in Burkina\u201d vaccine against malaria<\/p>\n\n\n\n
The World Health Organization (WHO) has approved and recommended a new vaccine to prevent malaria in children. R21\/Matrix-M immunizes children against this disease, and is deemed \"safe and effective\".<\/p>\n\n\n\n
The WHO director presented the new vaccine as a major step forward in the fight against malaria, a disease that is endemic in several countries. In Africa, the disease is one of the main causes of infant mortality.<\/p>\n\n\n\n
Malaria, which is transmitted by mosquitoes, hits children particularly hard in the African region, where almost half a million die from the disease every year. In 2021, the various means of combating the disease have not prevented 247 million cases worldwide, including 95% in Africa. This illustrates the salutary nature of this new vaccine.<\/p>\n\n\n\n
According to Prof. Halidou Tinto, Director of the Nanoro Clinical Research Unit (Burkina-Faso) and the main player in R21 research, in partnership with three other institutions, this vaccine will make a considerable contribution to the elimination of malaria.<\/p>\n\n\n\n
The R21 vaccine is the second malaria vaccine recommended by the WHO, following the RTS, S\/AS01 vaccine, which the Organization recommended in 2021. Both vaccines have been found to be safe and, if administered on a large scale, should have a definite impact on public health.<\/p>\n\n\n\n
Key features
malaria vaccine R21<\/p>\n\n\n\n
High efficacy when administered just prior to high fever
High public health impact in a wide range of transmission contexts
Cost-effective
Similarity of R21 and RTS vaccines
Good safety record in clinical trials<\/p>\n\n\n\n
At least 28 African countries are planning to introduce a WHO-recommended malaria vaccine as part of their national immunization programs.<\/p>\n\n\n\n
R21 malaria vaccine to be available to countries by mid-2024<\/p>","protected":false},"excerpt":{"rendered":"
...<\/p>","protected":false},"author":14,"featured_media":9802,"comment_status":"closed","ping_status":"closed","sticky":true,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[365],"tags":[],"class_list":["post-9801","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites"],"_links":{"self":[{"href":"https:\/\/jln.foasps.org\/en\/wp-json\/wp\/v2\/posts\/9801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jln.foasps.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jln.foasps.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jln.foasps.org\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/jln.foasps.org\/en\/wp-json\/wp\/v2\/comments?post=9801"}],"version-history":[{"count":1,"href":"https:\/\/jln.foasps.org\/en\/wp-json\/wp\/v2\/posts\/9801\/revisions"}],"predecessor-version":[{"id":10355,"href":"https:\/\/jln.foasps.org\/en\/wp-json\/wp\/v2\/posts\/9801\/revisions\/10355"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jln.foasps.org\/en\/wp-json\/wp\/v2\/media\/9802"}],"wp:attachment":[{"href":"https:\/\/jln.foasps.org\/en\/wp-json\/wp\/v2\/media?parent=9801"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jln.foasps.org\/en\/wp-json\/wp\/v2\/categories?post=9801"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jln.foasps.org\/en\/wp-json\/wp\/v2\/tags?post=9801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}